Unique Hyaluromimethic® Technology
Hyaluromimethic® Technology is BMG’s patented state of the art technology of modifying Sodium Hyaluronate on its hydroxylic bonds. This novel technology with its outstanding features is suitable for the development of topical and injectable products in dermatology, ophthalmology, periodontology and more.
Featured Products
Focused on what Matters
News
BMG Pharma and HTL sign a development agreement to manufacture BMG’s new biopolymer based on the Hyaluromimethic® Technology The agreement between BMG Pharma and HTL will allow BMG Pharma to…
Read MoreBMG0705 Nasal Spray and BMG0703A Mouth Rinse achieve statistically significant clinical results in preventing COVID-19 and other nasal infections BMG0705 Nasal Spray and BMG0703A Mouth Rinse showed efficiency in prevention…
Read MoreFRIULIA FOCUSES ON BMG PHARMA WITH AN INVESTMENT OF €2 MILLION The investment is aimed at supporting the Business Plan that includes about €9 million in investments over the next…
Read More